VIRX
Viracta Therapeutics, Inc.
Key Financials
Operating Income
$-50693000
↓ 0.2%
Net Income
$-51058000
↓ 3.8%
Shareholders' Equity
$18.3M
↓ 70.0%
Total Liabilities
$38.4M
↑ 10.0%
Cash & Equivalents
$12.3M
↓ 66.5%
EPS (Diluted)
$-1.32
↓ 1.5%
Revenue
$120000
↓ 94.2%
Long-term Debt
$16.9M
N/A
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 25-NSE | 7/10/2025 | View on SEC |
| SCHEDULE 13G | 2/14/2025 | View on SEC |
| 8-K | 2/5/2025 | View on SEC |
| 8-K | 1/31/2025 | View on SEC |
| 8-K | 1/24/2025 | View on SEC |
| 8-K | 1/17/2025 | View on SEC |
| 8-K | 12/26/2024 | View on SEC |
| 8-K | 11/29/2024 | View on SEC |
| 4 | 11/27/2024 | View on SEC |
| 4 | 11/27/2024 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | VIRX |
| Company Name | Viracta Therapeutics, Inc. |
| CIK | 1061027 |
| Sector | Pharmaceutical Preparations |
| Industry | Non-accelerated filer Smaller reporting company |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | 858-400-8470 |